News

MAY 17, 2023 | COMPANY | NEWS Liquid biopsy company Nonacus and genomic testing laboratory Informed Genomics officially opened their new Birmingham Headquarters yesterday with a ribbon-cutting ceremony led by Angela Douglas MBE, Deputy Chief Scientific Officer for NHS England. Nonacus, a leading liquid biopsy company, and genomic testing laboratory Informed Genomics, marked a significant…

MARCH 29, 2023 | COMPANY | NEWS The urine-based molecular test can quickly and accurately detect bladder cancer and streamline diagnosis, thereby reducing the need for invasive cystoscopies. Nonacus launched GALEAS® Bladder, a novel test for the non-invasive detection of bladder cancer at the European Association of Urology (EAU) Annual Meeting in Milan on 10-13th March 2023.…

MARCH 9, 2023 | COMPANY | NEWS Nonacus is delighted to announce its investment in CanSense: a Swansea-based start-up company focused on the early detection of bowel cancer through a simple blood test. CanSense’s test, which combines laser spectroscopy with artificial intelligence, is faster, less expensive and less invasive than a colonoscopy procedure and more…

November 24, 2022 | COMPANY | NEWS Nonacus has been ranked within the top three fastest growing tech companies in the U.K, and first in healthcare, at the prestigious 2022 Deloitte Tech Fast 50 awards. The Deloitte UK Technology Fast 50 is a ranking of the 50 fastest-growing technology companies in the UK. The rankings…

July 7, 2022 | ONCOLOGY | COMPANY | NEWS “We’ve created the first pan-cancer DNA sequencing panel that we know to be optimised for cell free DNA (cfDNA) in paediatric solid tumours” – Reda Stankunaite, Institute of Cancer Research Paediatric cancers are the leading cause of disease-related deaths among children who survive past infancy in…

May 17, 2022 | COMPANY | NEWS The latest results: 2022 update Last July we announced that Nonacus and the University of Birmingham had partnered to develop a non-invasive test for bladder cancer. The test uses highly sensitive liquid biopsy technology developed by Nonacus, and a panel of biomarkers validated by Dr Rik Bryan and…

November 11, 2021 | COMPANY | NEWS Researchers at The Centre For Genomic and Experimental Medicine, University of Edinburgh, have used Nonacus Cell3 Target technology to undertake targeted DNA methylation sequencing with the aim of finding DNA methylation specific breast cancer markers. This work is funded by Cancer Research UK. Nonacus spoke to Dr. Martyna Adamowicz from the…

March 8, 2021 | COVID-19 | SERVICE We are now offering a Whole Genome Sequencing service to support SARS-CoV-2 testing laboratories, enabling them to provide Day 2 testing for ‘Test to Release’ in the UK. Government regulations, recently announced, set out the minimum standards that private sector providers must meet for SARS-CoV-2 tests for people arriving…

December 18, 2020 | COMPANY Nonacus. The name behind non-invasive genomic diagnostics When Chris and Lee founded Nonacus in 2015 they had one singular purpose – to develop non-invasive DNA tests that would change the way genomic diagnostics was done. Choosing a name that would reflect this mission wasn’t easy. Based off the Latin term…